Sherman Says Lenvatinib Approval "Likely" as FDA Decision Date Nears
February 11th 2015With a deadline of April 14, the FDA will soon make its final approval decision on the oral multikinase inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
Read More
FDA Grants Breakthrough Status to PD-L1 Inhibitor MPDL3280A in NSCLC
February 2nd 2015The anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer that has progressed during or after platinum-based chemotherapy, as well as a targeted therapy for patients with EGFR- or ALK-positive tumors.
Read More
Incyte Medical Officer Elaborates on Ruxolitinib Benefit for Polycythemia Vera
January 29th 2015For additional insight on the published RESPONSE data and the use of ruxolitnib to treat polycythemia vera, we reached out to Richard Levy, MD, executive vice president and chief drug development and medical officer at Incyte, the company that co-manufactures ruxolitinib with Novartis.
Read More
Ramucirumab Improves Survival in Second-Line mCRC
January 12th 2015Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC), according to results from the phase III RAISE trial.
Read More
ODAC Unanimously Supports Approval of First Biosimilar
January 7th 2015In a 14-0 vote, the FDA's ODAC unanimously recommended approval of EP2006, a biosimilar version of filgrastim. If the FDA follows the recommendation, the drug would become the first biosimilar approved in the United States.
Read More
HR-Negative Subgroup Data Offer Silver Lining to Everolimus Frontline Failure in BOLERO-1
December 12th 2014Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer
Read More
Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent-tamoxifen, compared with standard tamoxifen alone, according to results from the phase III SOFT trial.
Read More
Chemo Alone May Be Optimal in HER2-Positive Patients With High TIL Levels
December 10th 2014Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.
Read More
Immunotherapeutic Strategies in Head and Neck Cancer
November 7th 2014Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.
Read More
Some Surgical Complications Greater With Bilateral Versus Unilateral Mastectomy
September 2nd 2014Postsurgery complications are infrequent among breast cancer patients undergoing surgery with reconstruction; however, according to a large database study, the rates of certain complications, including reoperation, blood transfusion, and implant loss, are higher with bilateral mastectomy versus unilateral mastectomy.
Read More
Giants of Cancer Care Heralded: Ceremony Honors 2nd Annual Giants Class
July 16th 2014The 2nd Annual Giants of Cancer Careâ„¢ Awards were presented at a ceremony held on May 30 in Chicago. The event recognized 16 oncology heroes whose groundbreaking contributions to the field have improved the lives of patients with cancer.
Read More
Survival Comparable With Bevacizumab, Cetuximab in mCRC
June 1st 2014Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with KRAS wild-type metastatic colorectal cancer
Read More
As Lung Cancer Screening Debate Continues, Study Projects Implementation Outcomes
May 14th 2014In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).
Read More
Emerging Treatments and Trends in Hematologic Malignancies: A Q&A With Anas Younes, MD
April 30th 2014At the 18th Annual International Congress on Hematologic Malignancies, Anas Younes, MD, sat down with Oncology & Biotech News to discuss trends in the management of hematologic malignances.
Read More